Enhertu cut breast cancer recurrence risk by 53% against T-DM1, but will lung toxicity affect its use?
Enhertu wins EU approval after cutting invasive recurrence or death risk by 53% versus T-DM1. Lung toxicity remains a key consideration.
Pharma & Biotech
Medical Devices & Diagnostics
Enhertu wins EU tumor-agnostic approval, but HER2 testing will decide its real impact
The European approval takes Enhertu beyond organ-specific oncology, although its clinical reach will depend on reliable HER2 testing, reimbursement and safety management.
Pharma & Biotech
Enhertu nears wider EU approval as HER2 testing moves deeper into solid tumor oncology
Find out how Enhertu’s EU recommendation could reshape HER2 targeted treatment for metastatic solid tumors.
Pharma & Biotech
Why ALX Oncology’s ASPEN-09 readout may matter beyond one HER2 breast cancer study
ALX Oncology has a CD47 signal. The harder test is whether ASPEN-09 can turn a tiny responder cohort into Phase 2 confidence.
Medical Devices & Diagnostics
Why Dana-Farber’s Enhertu biomarker study could change metastatic breast cancer diagnostics
Dana-Farber’s new study highlights Ignite Proteomics in Enhertu response prediction. Read what this could mean for metastatic breast cancer care.
Pharma & Biotech
Avacta (AIM: AVCT) FAP-Exd data challenges Enhertu on tumor selectivity ahead of Phase 1 start
Avacta Therapeutics (AIM: AVCT) has published preclinical data showing that its FAP-targeted payload delivery platform, FAP-Exd (AVA6103), outperforms the marketed antibody drug conjugate trastuzumab deruxtecan across three pharmacokinetic measures, with a Phase 1 clinical trial expected to begin in the first quarter of 2026. What the AI-generated comparator actually enables The methodological choice here deserves
Pharma & Biotech
Is ENHERTU plus pertuzumab on track to redefine first-line treatment in HER2-positive metastatic breast cancer?
EMA begins review of ENHERTU plus pertuzumab for first-line HER2-positive metastatic breast cancer. Find out what this means for frontline therapy options.
Pharma & Biotech
AstraZeneca, Daiichi Sankyo push Enhertu into early breast cancer with new FDA nod
AstraZeneca PLC and Daiichi Sankyo’s HER2-directed antibody-drug conjugate Enhertu (trastuzumab deruxtecan) has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for use in patients with HER2-positive early breast cancer who have residual invasive disease following neoadjuvant treatment and are at high risk of recurrence. The designation is based on positive results
Pharma & Biotech
Enhertu plus pertuzumab receives FDA approval for 1st-line HER2-positive metastatic breast cancer: Is the new standard of care here?
AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu (trastuzumab deruxtecan), in combination with pertuzumab, has received U.S. Food and Drug Administration approval as a first-line treatment for patients with unresectable or metastatic HER2-positive breast cancer, based on results from the DESTINY-Breast09 Phase III trial. The approval marks the first new frontline treatment in over a decade